article Open AccessTop 1% cited

Guidelines of care for the management of atopic dermatitis

Journal of the American Academy of Dermatology · 2014 · Vol. 71(2) · pp. 327–349

Robert Sidbury✉(Seattle Children's Hospital)Dawn Marie R. Davis(Mayo Clinic)David E. Cohen(New York University)Kelly M. Cordoro(University of California, San Francisco)Timothy G. Berger(University of California, San Francisco)James N. Bergman(University of British Columbia)Sarah L. Chamlin(Northwestern University)Kevin D. Cooper(Case Western Reserve University)Steven R. Feldman(Wake Forest University)Jon M. Hanifin(Oregon Health & Science University)Alfons Krol(Oregon Health & Science University)David J. Margolis(California University of Pennsylvania)Amy S. Paller(Northwestern University)Kathryn Schwarzenberger(University of Tennessee Health Science Center)Robert A. Silverman(IS practice)Eric L. Simpson(Oregon Health & Science University)Wynnis L. Tom(University of San Diego)Hywel C Williams(National Health Service)Craig A. Elmets(University of Alabama at Birmingham)Julie Block(National Eczema Association)Christopher G. Harrod(American Academy of Dermatology)Wendy Smith Begolka(American Academy of Dermatology)Lawrence F. Eichenfield(University of San Diego)

View via DOI Publisher page

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Asthma and respiratory diseasesMedicineAtopic dermatitisGuidelineDermatologyIntensive care medicinePathology

MeSH terms

Anti-Infective AgentsAzathioprineDermatitis, AtopicHistamine AntagonistsHumansImmunologic FactorsInterferon-gammaMethotrexateMycophenolic AcidPhototherapyCyclosporine

Citations

861

FWCI

56.04

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t